Table 3.
IPs accumulation in Neuro2A cells, and in Neuro2A cells stably expressing wt α1A-, α1B- and α1D-adrenoceptors, and two truncated α1D-adrenoceptor variants
| (A) Cirazoline-stimulated IPs accumulation | |||||
| Receptor | IPs/total I (basal level) (% conversion) | IPs/total I (+cirazoline) (% conversion) | Stimulation (individual exp.) (fold) | pEC50 (cirazoline) | n |
| α1D-AR (wt) | 3.90±0.35 | 7.11±1.30 | 1.81±0.23 | 7.16±0.12 | 5 |
| Δ1–17α1D-AR | 4.22±0.68 | 9.05±1.16 | 2.21±0.22 | 7.18±0.20 | 5 |
| Δ1–58α1D-AR | 4.82±1.67 | 19.74±3.29 | 5.22±1.05 | 7.58±0.09 | 6 |
| α1A-AR | 3.33±0.39 | 13.68±3.09 | 4.45±1.09 | 7.43±0.16 | 6 |
| Neuro2A cells | 4.67±1.10 | no effect | N.C. | 3 | |
| (B) Phenylephrine (PE)-stimulated IPs accumulation | |||||
| Receptor | IPs/total I (basal level) (% conversion) | IPs/total I (+ PE) (% conversion) | Stimulation (individual exp.) (fold) | pEC50 (PE) | n |
| α1D-AR (wt) | 2.02±0.19 | 2.53±0.24 | 1.25±0.02 | 6.63±0.12 | 6 |
| Δ1–17α1D-AR | 1.65±0.27 | 2.82±0.68 | 1.65±0.16 | 6.72±0.10 | 4 |
| Δ1–58α1D-AR | 1.43±0.10 | 5.51±0.72 | 3.80±0.34 | 7.43±0.05 | 6 |
| α1A-AR | 2.17±0.30 | 4.12±0.44 | 1.94±0.07 | 5.80±0.08 | 6 |
| α1B-AR | 2.32±0.22 | 7.38±0.76 | 3.27±0.36 | 6.48±0.04 | 6 |
The basal-, cirazoline-, and phenylephrine-stimulated percent conversion of [3H]-inositol to [3H]-inositol phosphates, and the fold increase in IPs accumulation induced by the agonists are shown. Also shown are the pEC50 values of cirazoline and phenylephrine. In (A) the results with cirazoline, and in (B) the results with phenylephrine as shown. The incubation time with drugs was 50 min.